KRBP News and Press, Kiromic BioPharma Inc. From 03/09/23

2023-03-09 14:31:53 ET Penny stocks are shares of small companies with a price of less than $5 per share. These stocks are known for their high volatility and low liquidity, making them a risky investment option. However, they also offer some unique benefits and opportunities for traders an...

Favorable Safety Results are Last Component Needed to Complete the Nonclinical Module of the Company’s IND Application IND Submission and Activation of Clinical Trial Process on Track for the First Quarter and Second Quarter of this Year, Respectively Kiromic BioPharma,...

ISS and Glass Lewis Join the Kiromic Board of Directors in Recommending Stockholders Vote “ FOR ” for All Three Proposals at the Special Meeting of Kiromic Stockholders to be Held on March 7, 2023 Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the...

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-o...

Kiromic BioPharma ( NASDAQ: KRBP ) appoints Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately. Dr. Mirandola has served as the Company’s Vice President of R&D and Clinical Translation since September 2021 and his previous ro...

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies wit...

Penny stocks are beginning to heat up again. While the broader stock market indexes waiver in the wake of the latest Federal Reserve meeting minutes, traders are charging ahead & buying into volatile stocks. One of the biggest reasons behind the shift from investing and into trading is ...

Construction Completion is One of the Pre-requisites to Beginning the Deltacel™ Clinical Trial Activation Later This Year and Addresses a Key Clinical Hold Citation Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”) , ...

IND for Non-Engineered Deltacel/KB-GDT ™ to be Submitted in the Second Half of 2022 with Beginning of Clinical Trial Activation Expected by Year-End Three Additional IND Filings Will Expand the Company’s Pipeline to Five Allogeneic Gamma Delta T-cell Clin...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kiromic BioPharma ( KRBP ) stock is taking off on SRA news. This has it planning to submit three new NDAs. These will focus on GDT allogeneic therapies. Source: Shutterstock Kiromic BioPharma (NASDAQ: ...